A human antibody specific for SIRPα reprograms macrophages and promotes antibody mediated anti-cancer activity.
Several T cell immune checkpoint blockade therapies have shown initial successes in multiple cancers. However, significant issues remain, including tumor relapse, severe toxicities, and a lack of efficacy in most patients. SIRPα, commonly known as the "do not eat me signal", is a monocyte...
Saved in:
| Main Authors: | Keifer G Kurtz, Irina Lebedeva, Stephanie A Pierre, David Andrew, Yu-Rou Liao, Daisy Ambriz, Olivia Vergnolle, Leyi Shen, Elizabeth Nyakatura, Manuel Baca, David A Scheinberg |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2025-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0321169 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Enhancing tumor immunotherapy with smart nanoparticles for reprogramming macrophages and blocking the CD47/Sirpα pathway
by: Zubair Hussain, et al.
Published: (2025-06-01) -
Preclinical characterization of the novel anti-SIRPα antibody BR105 that targets the myeloid immune checkpoint
by: Juan Chen, et al.
Published: (2022-03-01) -
Development of Fully Human Antibodies Targeting SIRPα and PLA2G7 for Cancer Therapy
by: Seungmin Shin, et al.
Published: (2025-03-01) -
Expression of SIRPα-Fc by oncolytic virus enhances antitumor efficacy through tumor microenvironment reprogramming
by: Qingzhe Yang, et al.
Published: (2025-02-01) -
Nicotine Suppresses Phagocytic Ability of Macrophages by Regulating the miR-296-3p–SIRPα Axis
by: Zhen Liu, et al.
Published: (2023-01-01)